QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Substantial investment needed to meet alzheimers diagnosis targets
Hopes are high for the first disease modifying treatments in Alzheimer’s disease to be approved on the European market, but many challenges remain. Quantify Research colleagues Anders Gustavsson and Lena Jacobs are co-authors of a study on the capacity constraints for diagnosing Alzheimer’s disease in Sweden.
More Alzheimer specialists are needed to reduce expected waiting times approaching 5 years for individuals who […]
NORDSTAR describes distinct trajectories of development of severe asthma – on the road to changing the natural history of severe asthma?
The natural history of severe asthma is complex and poorly understood, and until recently we were unable to effectively predict the progression of the disease. To shed light on this important area, we are delighted to share our latest study from the pan-Nordic research collaboration NORDSTAR, entitled “Severe asthma trajectories in adults: findings from the NORDSTAR cohort” just published in the September issue of the European Respiratory […]
Increasing burden of fatty liver disease
Extensive article today in the Swedish newspaper Dagens Nyheter on the increasing burden of fatty liver disease (NAFLD), including an interview with Associate Professor Hannes Hagström, co-creater of the HERALD liver data platform together with Quantify Researchs Emilie Toresson Grip and Oskar Ström.
Key messages of the article are:
– Extensive need to raise awareness of fatty liver disease, to be considered in e.g. routine follow-up and risk […]
New publication on burden of Pneumococcal disease
Pneumococcal disease (PD) is a major cause of clinical and economic burden worldwide, yet the burden of PD in Swedish adults and its relationship with medical risk factors (MRFs) is largely unknown. In collaboration with MSD, Quantify Research’s Martina Aldvén estimated the burden of PD in the form of pneumonia, meningitis, and septicemia diagnosed in the hospital setting amongst Swedish adults stratified into three cohorts based on […]